New drugs for the treatment of complicated intra-abdominal infections in the era of increasing antimicrobial resistance

Ling-Shan Syue, Yen Hsu Chen, Wen-Chien Ko, Po Ren Hsueh

Research output: Contribution to journalShort survey

23 Citations (Scopus)


The continuing increase in multidrug-resistant organisms (MDROs) worldwide has created new challenges in treating complicated intra-abdominal infections (cIAIs). A number of novel antimicrobial agents have been developed against resistant pathogens. To target extended-spectrum β-lactamase (ESBL)-producing pathogens, novel β-lactam antibiotics, such as ceftolozane/tazobactam, ceftazidime/avibactam, aztreonam/avibactam, imipenem/relebactam and S-649266, are antimicrobial alternatives for cIAIs. Two new drugs, eravacycline and plazomicin, have activity against Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae, carbapenem-resistant Acinetobacter baumannii and ESBL-producers. New lipoglycopeptides and oxazolidinones provide feasible options against resistant Gram-positive pathogens. These novel antimicrobials may play a role in improving the clinical outcomes of cIAIs caused by MDROs.

Original languageEnglish
Pages (from-to)250-258
Number of pages9
JournalInternational journal of antimicrobial agents
Issue number4
Publication statusPublished - 2016 Apr 1


All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

Cite this